What's new? Log in Free sign up

Precipio (PRPO) News and press releases

Company Profile

News

From Benzinga Pro

Precipio Sees Q3 Revenue $4.5M Vs $4M Est.

Earnings, News, Guidance

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022.The

Precipio Continues To Sign New HemeScreen Customers Expected To Bring Total Q4 HemeScreen Revenues To An Estimated $1.2M

News, Contracts

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M.In a recent announcement, the

Precipio Reduces Product Revenue Result Needed For Cash Flow Breakeven From $8M To $6M Annually, Or $1.5M Per Quarter, 25% Below Previous Estimates

Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required

Stocks That Hit 52-Week Lows On Thursday

During the session on Thursday, 461 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

Monday's session saw 175 companies set new 52-week lows.

Press releases

From Benzinga Pro

Precipio Announces Q3-2023 Shareholder Update Call

News, Press Releases

NEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call

Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-2022

Health Care, Press Releases

NEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and

Precipio Reduces Product Revenue Result Needed for Cash Flow Breakeven

News, Press Releases

NEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the

Precipio Takes Final Step Towards Regaining Nasdaq Compliance

NEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) today announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the

Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of Plan

Health Care, Press Releases

NEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.